Pharmacokinetic and therapeutic outcome in melanoma cells, of the administration of symmetric and asymmetric cationic photosensitizers.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97458
Title:
Pharmacokinetic and therapeutic outcome in melanoma cells, of the administration of symmetric and asymmetric cationic photosensitizers.
Authors:
Haylett, Ann K; Ross, S; Truscott, T G; Moore, James V
Abstract:
The response of melanoma cell lines to a range of novel cationic photosensitizers based on either a protoporphyrin or a mesotetra(4-carboxylphenyl)porphine molecule, has been examined. The drugs varied in terms of either their symmetry or their side chain configuration. The effect of these variables on drug uptake and photodynamic cell kill were tested. The absorption wavelengths for the drugs were measured and a shift to the red was seen in the presence of cells. Drug uptake was measured and the cationic sensitizers had a relatively high uptake when compared to anionic HpD. The efficiency of the drugs in causing cell kill was expressed in terms of clonogenic cell survival. The asymmetric photosensitizers were more efficient in destroying mouse and human melanoma cells than the clinically used anionic HpD, which was in turn more efficient than the symmetric sensitizers tested.
Affiliation:
Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.
Citation:
Pharmacokinetic and therapeutic outcome in melanoma cells, of the administration of symmetric and asymmetric cationic photosensitizers. 1995, 88 (2):191-9 Cancer Lett.
Journal:
Cancer Letters
Issue Date:
27-Jan-1995
URI:
http://hdl.handle.net/10541/97458
DOI:
10.1016/0304-3835(94)03632-S
PubMed ID:
7874693
Type:
Article
Language:
en
ISSN:
0304-3835
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorHaylett, Ann Ken
dc.contributor.authorRoss, Sen
dc.contributor.authorTruscott, T Gen
dc.contributor.authorMoore, James Ven
dc.date.accessioned2010-04-27T13:31:00Z-
dc.date.available2010-04-27T13:31:00Z-
dc.date.issued1995-01-27-
dc.identifier.citationPharmacokinetic and therapeutic outcome in melanoma cells, of the administration of symmetric and asymmetric cationic photosensitizers. 1995, 88 (2):191-9 Cancer Lett.en
dc.identifier.issn0304-3835-
dc.identifier.pmid7874693-
dc.identifier.doi10.1016/0304-3835(94)03632-S-
dc.identifier.urihttp://hdl.handle.net/10541/97458-
dc.description.abstractThe response of melanoma cell lines to a range of novel cationic photosensitizers based on either a protoporphyrin or a mesotetra(4-carboxylphenyl)porphine molecule, has been examined. The drugs varied in terms of either their symmetry or their side chain configuration. The effect of these variables on drug uptake and photodynamic cell kill were tested. The absorption wavelengths for the drugs were measured and a shift to the red was seen in the presence of cells. Drug uptake was measured and the cationic sensitizers had a relatively high uptake when compared to anionic HpD. The efficiency of the drugs in causing cell kill was expressed in terms of clonogenic cell survival. The asymmetric photosensitizers were more efficient in destroying mouse and human melanoma cells than the clinically used anionic HpD, which was in turn more efficient than the symmetric sensitizers tested.en
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshCations-
dc.subject.meshCell Survival-
dc.subject.meshCulture Media-
dc.subject.meshHumans-
dc.subject.meshMelanins-
dc.subject.meshMelanoma-
dc.subject.meshMelanoma, Experimental-
dc.subject.meshMice-
dc.subject.meshMice, Inbred C57BL-
dc.subject.meshPhotochemotherapy-
dc.subject.meshPhotosensitizing Agents-
dc.subject.meshProtoporphyrins-
dc.subject.meshStructure-Activity Relationship-
dc.titlePharmacokinetic and therapeutic outcome in melanoma cells, of the administration of symmetric and asymmetric cationic photosensitizers.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.en
dc.identifier.journalCancer Lettersen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.